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A B S T R A C T
Purpose
Although CD49d is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL),
definitive validation evidence is lacking. A worldwide multicenter analysis was performed using
published and unpublished CLL series to evaluate the impact of CD49d as an overall (OS) and
treatment-free survival (TFS) predictor.
Patients and Methods
A training/validation strategy was chosen to find the optimal CD49d cutoff. The hazard ratio (HR)
for death and treatment imposed by CD49d was estimated by pooled analysis of 2,972 CLLs; Cox
analysis stratified by center and stage was used to adjust for confounding variables. The
importance of CD49d over other flow cytometry–based prognosticators (eg, CD38, ZAP-70) was
ranked by recursive partitioning.
Results
Patients with  30% of neoplastic cells expressing CD49d were considered CD49d. Decrease
in OS at 5 and 10 years among CD49d patients was 7% and 23% (decrease in TFS, 26% and
25%, respectively). Pooled HR of CD49d for OS was 2.5 (2.3 for TFS) in univariate analysis. This
HR remained significant and of similar magnitude (HR, 2.0) in a Cox model adjusted for clinical and
biologic prognosticators. Hierarchic trees including all patients or restricted to those with
early-stage disease or those age  65 years always selected CD49d as the most important flow
cytometry–based biomarker, with negligible additional prognostic information added by CD38 or
ZAP-70. Consistently, by bivariate analysis, CD49d reliably identified patient subsets with poorer
outcome independent of CD38 and ZAP-70.
Conclusion
In this analysis of approximately 3,000 patients, CD49d emerged as the strongest flow cytometry–
based predictor of OS and TFS in CLL.
J Clin Oncol 32:897-904. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Chronic lymphocytic leukemia (CLL) shows a
highly variable clinical course,1 which can be pre-
dicted by a number of biologic markers, including
the mutational status of immunoglobulin heavy
variable (IGHV) gene,2-4 genomic abnormalities,5
and expression of the surface marker CD382,6 and of
the intracytoplasmic protein ZAP-70.7-9
CD49d, the 4 subunit of the integrin het-
erodimer41, is a surface molecule, the expression
of which promotes microenvironment-mediated
proliferation of CLL leukemic cells10-13 and identi-
fies a subgroup of patients characterized by progres-
sive course and short survival.14-20 To translate
CD49d expression assessment at the clinical level, a
number of open issues remain to be clarified, in-
cluding: one, definition and validation of the opti-
mal CD49d cutoff for predicting CLL survival and
progression; two, robustness of CD49d expression
as a prognostic biomarker when challenged against
potential confounding variables; and three, estima-
tion of the relative prognostic power of CD49d in
comparison with CD38 and ZAP-70, two flow
cytometry–based biomarkers widely used for CLL
outcome stratification.
To address these issues, we carried out a world-
wide multicenter initiative to evaluate the prognos-
tic utility of CD49d in CLL, which combined
individual patient data (IPD) from all previously
reported studies with a large unpublished valida-
tion series.
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PATIENTS AND METHODS
Identification of Previous Studies and Collection of Data
A Medline search (http://www.ncbi.nlm.nih.gov/pubmed/) was per-
formed on April 30, 2011, using the terms “CD49d” AND “chronic lympho-
cytic leukemia.” References of all the retrieved articles were also scanned for
additional relevant citations. Abstracts of American Society of Hematology
annual meetings (years 2006 to 2010) were also screened for “CD49d” OR
“integrin” keywords. A total of 44 studies and 70 abstracts were retrieved
through Medline search and manual screening, respectively. Studies were
included in the pooled analysis if they met the following criteria: one, included
at least 50 CLLs; two, evaluated CD49d expression of CLL cells by flow cytom-
etry; three, reported the association between CD49d expression and survival
(overall survival [OS]) and/or disease progression (treatment-free [TFS]
and/or progression-free survival [PFS]). To avoid inclusion of duplicated data,
patient series published multiple times were considered only once.
Overall, eight published studies (seven full-length reports and one ab-
stract) were identified for inclusion in pooled analysis, all fulfilling the eligibil-
ity criteria and reporting independent results. Median quality score among the
published full-length studies was judged high (median value, 5; range, 5 to 7).
Of these studies, two were prospective,15,19 two recruited consecutive pa-
tients,16,20 and one recruited patients from multiple centers.20 Corresponding
authors were contacted and invited to participate. In May 2011, the proposed
analysis plan was shared with all authors, and IPD were requested. All authors
agreed to send IPD in spreadsheet format, which were merged after variable
renaming and/or recoding as needed. Variables are listed in Table 1. Contrib-
utors from seven clinical centers located in either the United States (two
centers) or the European Union (three centers in Italy, one in Germany, and
one in United Kingdom) provided IPD from the published cohorts. Addition-
ally, four centers added updated follow-up and unpublished data on addi-
tional patients. The final data set included IPD from 3,267 patients. IPD of 295
patients were excluded for missing data (235 missing end point, 60 missing
CD49d). IPD of the remaining 2,972 patients with CLL were included in the
final analysis (1,556 published; 1,416 unpublished; CONSORT diagram
shown in Fig 1).
Stability of CD49d was evaluated in paired samples collected at different
time points (interval between sampling, 0.7 to 88.8 months; mean, 23.7
months) in 104 patient cases from the published cohort. In these patient cases,
the first sample was collected at diagnosis, and the second sample was collected
before therapy (n 99) or at relapse (n 5).
The study received approval from each local institutional review board
and was conducted in accordance with the Declaration of Helsinki. The meta-
analysis plan is available on request. This report has been checked with
PRISMA checklist (http://www.prisma-statement.org; Data Supplement).
Statistical Analysis
We adopted a training/validation strategy to determine the optimal
cutoff value of CD49d to predict OS (Data Supplement). The 1,556 patients
from the published cohorts served as training series, and the 1,416 patients
from the unpublished cohorts served as validation series. After having estab-
lished and validated the optimal cutoff value, the training and validation series
were merged for pooled analysis. Study heterogeneity and quality as well as
publication bias were evaluated as detailed in the Data Supplement. Log hazard
ratio (HR) of CD49d expression and corresponding SE were estimated in each
study using univariate Cox proportional regression and combined in a pooled
analysis with the fixed-effect model.21-23 To test the independence of the
prognostic value of CD49d expression, we performed a comprehensive mul-
tivariable Cox model with backward stepwise elimination of nonsignificant
covariates. All Cox models were stratified for study site and clinical stage of
disease. Models with and without CD49d expression and other covariates were
compared using log-likelihood/log-likelihood ratio, concordance index (C-
index), and net reclassification improvement (NRI).24-26
Recursive partitioning27,28 was used to study the hierarchic importance
of CD38, ZAP-70, and CD49d expression in predicting CLL survival. Survival-
tree stability was assessed using the random survival model method.29 Addi-
tional details are reported in the Data Supplement. Statistical analyses were
carried using R software (http://www.r-project.org).
RESULTS
General Characteristics of Patients
Characteristics of patients with CLL in the training and validation
series were comparable. Although the validation series had shorter
follow-up resulting from a more recent year of diagnosis, 5- and
10-year OS and TFS were similar (Table 1).
In both the training and validation series, distribution of prog-
nostic biomarkers (eg, presence of del11q, del17p, unmutated IGHV,
Table 1. Patients Demographic and Clinical Characteristics
Characteristic
Published Cohort
(n  1,556)
Unpublished
Cohort (n 
1,416)
No. % No. %
Age, years
Median 64 63
IQR 56-71 55-71
Male sex 961 62 898 63
Year of diagnosis
Median 2003 2007
IQR 1998-2005 2002-2009
Follow-up, years
Median 6.9† 4.0†
Range 0-36 0-43
Deaths 324† 21 171† 12
Stage‡
Early 843 55 823 58
Intermediate 568 37 513 36
Advanced 134† 9 75† 5
ALC,  109/L
Median 15 13
IQR 9-34 8-27
B-ALC,  109/L
Median 10 9
IQR 5-19 5-17
2M  ULN 544 52 439 57
del11q 120 9 103 10
del17p 75 6 75 7
Unmutated IGHV 487 37 478 42
ZAP-70 positive 449 40 555 40
CD38 464 31 406 29
CD49d 587 38 511 36
OS
5 year 90 92
10 year 73 80
TFS
5 year 57 59
10 year 39 42
NOTE. Differences between published and unpublished cohorts were eval-
uated using 2 or Wilcoxon test.
Abbreviations: ALC, absolute lymphocyte count; B-ALC, absolute B-cell
count; 2M, 2-microglobulin; IQR, interquartile range; OS, overall survival;
TFS, treatment-free survival; ULN, upper limit of normal.
Estimated by inverted censoring.
†P  .01.
‡Early stage, Binet A or Rai 0; intermediate stage, Binet B or Rai I to II;
advanced stage, Binet C or Rai III to IV.
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positivity for ZAP-70 and CD38) was similar and consistent with that
expected in newly diagnosed patients with CLL.4,9 Prevalence of
CD49d expression, as computed according to the original studies in
the published series or using the 30% cutoff in the unpublished series,
was also comparable.
Determination of the Optimal Cutoff of CD49d
Expression to Predict Survival in CLL
High CD49d expression was always associated with shorter OS
and/or disease progression (TFS) in CLL.14-20,30 However, heteroge-
neous cutoffs (ie, 30% and 45%) and procedures for cutoff determi-
nation were employed (Data Supplement).
To determine the optimal cutoff value of CD49d expression to
predict OS in CLL, we adopted a training/validation strategy. In the
training series, percentage of CD49d-expressing CLL cells followed a
U-shaped distribution, with the vast majority (92%) of cases cluster-
ing between 0% and 30% or 50% and 100% (Fig 2A); moreover,
CD49d values seemed stable over time in consecutive samples (Data
Supplement). Both features have been considered evidence of the
robustness of CD49d as a clinically useful prognosticator in CLL.14,31
Multiple statistical approaches were applied in the training series to
identify the optimal cutoff for CD49d expression. When examining
the functional form of the relationship between CD49d expression
and OS in martingale residual plot,32 the local regression line failed to
indicate a clear step suggestive of a cutoff point, although a slight
inflection could be recognized between 20% and 40% (Fig 2B). Simi-
larly, both a data-driven (ie, median) and three outcome-driven
methods (ie, Maxstat, Rpart, C-index) failed to agree on a single
common cutoff for CD49d, although a value close to 30% was selected
by two methods (Data Supplement). Therefore, we decided to validate
both the 30% and 45% cutoff values for CD49d expression even if the
shift from 30% to 45% changed the classification of CD49d expression
status in a minority of patients (3%; Data Supplement). According to
a Cox analysis for OS stratified by center and disease stage in the
validation series, the 30% cutoff had a slightly higher HR (2.50 v 2.49;
Data Supplement) and discrimination of patient outcome (C-index,
0.61 v 0.59; P  .001) compared with the 45% cutoff. These data
validate 30% as the best cutoff to code CD49d expression status to
predict OS in patients with CLL.
Prognostic Impact of CD49d in Pooled Analysis
Training and validation cohorts were merged for pooled analysis
of OS and TFS using the 30% cutoff for recoding CD49d expression
status. All single-center series contributing to the training and valida-
tion cohorts were confined within the tolerance limit bands in funnel
plots, thus ruling out publication biases (Data Supplement). No sig-
nificant heterogeneity was documented by either fixed (Q test, P 
.39) or random (I2, 5%) effect models, suggesting little variation in
study outcomes among series.
In the pooled analysis, CD49d patients had a significantly in-
creased hazard of death (HR, 2.5; 95% CI, 2.1 to 3.0; Fig 2C), translat-
ing into a significantly lower OS probability at both 5 (87%v94%) and
10 years (62% v 84%) compared with CD49d patients (Fig 2D).
Also, CD49d patients had a significantly increased hazard of being
treated (HR, 2.3; 95% CI, 2.0 to 2.6), translating into a significantly
lower probability of remaining treatment free at both 5 (42% v 68%)
and 10 years (24% v 50%) compared with CD49d patients (Fig 3).
Estimates of 5- and 10-year OS and TFS were similar when analysis
was restricted to the validation cohort (Data Supplement). These data
confirm that CD49d expression in30% of CLL cells has a detrimen-
tal impact on both OS and TFS that is reproducible in patient cohorts
from different institutions.
Finally, in the pooled series, biologic covariates used for compar-
ison with CD49d (eg, CD38, ZAP-70, IGHV, del11q, and del17p) had
the expected association with OS and TFS (Data Supplement).4-9
Prognostic Impact of CD49d in Multivariable Analyses
To study the potentially confounding effect of other variables on
the prognostic power of CD49d expression, we performed various
adjustments to a Cox proportional hazard model stratified for study
site in a cohort of 1,117 patient cases with all prognostic information
available. No major differences were observed when comparing this
1,117–patient case cohort with remaining patient cases with respect to:
one, trend of OS curves; two, distribution of the main clinicobiologic
features; or three, 5- and 10-year OS estimates (Data Supplement).
By Cox analysis for OS, CD49d CLL had a two-fold increased
risk of death (HR, 2.0; 95% CI, 1.4 to 3.0) after adjusting for disease
stage, sex, age, and other clinical and biologic prognostic factors (eg,
absolute lymphocyte count [ALC] and 2-microglobulin [2M] val-
ues, presence of del11q and del17p, IGHVmutation status, CD38 and
ZAP-70 expression). In the final multivariable model, CD49d turned
out to be the sole flow cytometry based–marker with independent
prognostic relevance for OS. The only other independent predictors of
OS were age, sex, IGHV mutation status, del17p, and ALC (Table 2).
In a model excluding CD49d, both ZAP-70 (HR, 1.60; 95% CI,
1.06 to 2.41) and CD38 (HR, 1.56; 95% CI, 1.08 to 2.26) regained
independent prognostic value (Data Supplement). Moreover, ad hoc
meta-analyses for ZAP-70 (2,504 patient cases) and CD38 (2,876
patient cases) failed to find heterogeneity in the investigated cohorts,
and the pooled effect, estimated in a fixed-effect model, was as ex-
pected (Data Supplement).6,9,33-35 Finally, correlation among CD49d,
IPD retrieved for detailed evaluation
(N = 3,267)
Potentially valid IPD
(n = 3,032)
Valid IPD
(n = 2,972)
CD49d cutoff testing cohort
(n = 1,556; published)
CD49d cutoff validation cohort
(n = 1,416; unpublished)
IPD excluded for missing CD49d data
(n = 60)
IPD excluded for missing OS
(n = 235)
Pooled analysis
(n = 2,972)
Fig 1. Study flow diagram. IPD, individual patient data; OS, overall survival.
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CD38, and ZAP-70 expression levels was mild, and no evidence of
collinearity was found among these flow cytometry–based markers or
between CD49d and IGHV gene status (Data Supplement). Of note,
according to our multivariable analysis, IGHV mutation status
seemed to be a better prognostic marker than ZAP-70, in keeping with
some reports35-37 but in disagreement with others.8,9
Comparison of the models with and without CD49d by several
prediction performance measures (log-likelihood/log-likelihood ra-
tio, C-index, NRI) indicated that omission of CD49d significantly
reduced the prognostic power of the model. In this regard, the impact
of CD49d exclusion from the model was similar to that of the exclu-
sion of age or IGHV gene status and stronger than the exclusion of
del17p, sex, and ALC (Data Supplement).
Similar results were obtained in a model in which2M and ALC
values were excluded to increase the cohort of patient cases with all
variables available (n 1,655; Data Supplement). Multivariable anal-
yses also selected CD49d expression as an independent predictor of
TFS in CLL (Data Supplement).
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Fig 2. (A) Histogram of CD49d expres-
sion for published cohort. (B) Martingale
residual plot: CD49d (x-axis) versus mar-
tingale residuals (y-axis) for published
cohort. (C) Forest plot of overall survival
(OS) hazard ratio (HR) in CD49d versus
CD49d patients (individual patient data
[IPD] for 2,972 patients; CD49d recoded at
cutoff  30%). Solid boxes indicate HR in
each study with dimensions proportional
to weights (inverse of variance); horizontal
lines indicate 95% CIs; diamond indicates
pooled HR. (D) Kaplan-Meier curves of OS
of IPD for 2,972 patients; CD49d recoded
at cutoff  30% (log-rank P  .001).
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Prognostic Impact of CD49d Among Flow
Cytometry–Based Markers
To test the relative importance of the three main flow cytometry–
based prognostic variables CD49d, CD38, and ZAP-70 as predic-
tors of OS in CLL, we built a hierarchic full-grown tree model by
recursive partitioning analysis (Appendix Fig A1, online only).
CD49d was selected at the first split as the most important variable.
The optimal tree-pruning level was at the first branching (com-
plexity parameter, 0.045), confirming the results of multivariable
Cox model and showing that in a hierarchic model, no additional
prognostic power was given by CD38 or ZAP-70 after CD49d was
considered. CD49d was also at the first split in tree models devel-
oped in 1,666 patients with early-stage disease and in 1,664 patients
age 65 years as well as when using patient cases from the valida-
tion cohort only (Data Supplement). These results were internally
validated by tree analysis in 1,000 bootstrap samples in which
CD49d was always selected over CD38 and ZAP-70 as the most
important variable associated with the greatest reduction in pre-
dictive error (data not shown).
Consistent with recursive partitioning analysis, bivariate survival
curves showed that CD49d, when expressed over the established cut-
off, also reliably identified subsets with worse prognosis in term of OS
and TFS regardless of CD38 or ZAP-70 status (Appendix Fig A2,
online only).
Overall, these data show that among CLL phenotypic markers,
CD49d has a greater prognostic importance than CD38 or ZAP-70
and demonstrate the additional value of CD49d testing when CD38
and ZAP-70 information is available.
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DISCUSSION
In this pooled analysis of 2,972 patients with CLL, CD49d was an
independent predictor of OS and TFS and retained its prognostic
value after adjusting for other well-established biologic prognostica-
tors (2M, ALC, CD38, ZAP-70, IGHV gene status, cytogenetic aber-
rations). Indeed, CD49d was among the most important prognostic
variables, along with age and IGHVgene status. CD49d emerged as the
strongest flow cytometry–based prognostic marker, with greater
prognostic value than CD38 and ZAP-70.
Using a training/validation strategy, we established the 30% cut
point as the most useful threshold for classification of CD49dCLL.
Notably, in this large series as well as in previous studies,14,15,17 CD49d
expression showed a bimodal distribution, with most patients show-
ing either very high or very low levels of expression. This fact mini-
mized the number of patient cases with borderline CD49d expression
clustered around the cutoff, making CD49d a pragmatic choice of
biomarker for reliable prognostication of CLL. In contrast, other
markers (eg, ZAP-70) often have expression values distributed around
the cutoff,7,8,38 making confident prediction of clinical outcome
more difficult.
Methodologic factors of the flow cytometric procedure for
CD49d detection investigated here, including mAb clone, mAb fluo-
rochrome conjugation, or immunofluorescence strategy (two v three
colors), did not have any effect on the overall percentage of CD49d
patient cases, again underscoring the robustness of CD49d as a prog-
nosticator. Nevertheless, for clinical routine analyses, we suggest at
least a three-color strategy that includes CD49d in a single combina-
tion along with CD19 and CD5. This will exclude from analysis the
majority of contaminating normal CD5 B cells, known to express
high levels of CD49d.39 Altogether, CD49d emerges as a surface
marker, the expression of which can be easily investigated in routine
clinical practice, is highly reproducible, and is not subject to variation
resulting from the application of different methodologies.
As shown by multivariable analyses of the pooled data, CD49d was
selected as an independent predictor of OS, along with age, IGHVmuta-
tion status, del 17p, sex, and ALC in models including all investigated
variables and in models excluding2M and ALC to increase the number
of patient cases. ZAP-70 and CD38 were discarded from the comprehen-
sive final multivariable model but were both retained when CD49d
was excluded from analysis, in agreement with literature data.2,4,6-8
In accordance with these results, a hierarchic model restricted to
flow cytometric prognostic markers (ZAP-70, CD38, and CD49d)
located CD49d at the top of the branching among the entire cohort
of patients as well as among young patients and those with early-
stage disease. Therefore, CD49d turned out to be the best flow
cytometry– based marker to stratify prognosis of patients with
CLL. Moreover, as demonstrated by bivariate analyses, CD49d
expression reliably identified subsets of patients with poorer out-
come independent of CD38 or ZAP-70 status. On this basis, we
believe that testing CD49d expression in routine clinical practice
should be considered in the baseline prognostic assessment of
patients with newly diagnosed CLL as well as to refine prognostic
evaluation in patients already stratified by CD38 and ZAP-70.
Stability of CD49d expression level over time, demonstrated both
here and previously,14,31 should allow reliable evaluation of CD49d
at any point during the watch-and-wait interval.
The microenvironmental dependency of CLL cells for prosur-
vival signals, both integrin and B cell–receptor (BCR) mediated, has
been recently highlighted by the emerging role of Bruton’s tyrosine
kinase (BTK) inhibitors as promising new therapeutic agents in CLL
and other B-cell malignancies.40 In particular, both clinical studies and
in vitro observations have concordantly indicated that BTK inhibition
results in a reduced microenvironmental retention of CLL cells in
tissue sites because of impaired integrin- and chemokine receptor–
mediated tissue homing.41-43 In this context, it is perhaps not surpris-
ing that CD49d (4 subunit of integrin heterodimer41; one of the
most potent mediators of cell-matrix and cell-cell interactions10) and
IGHV gene mutational status of BCR both emerge as the strongest
predictors of short OS and TFS in CLL. Given the retrospective nature
of this study, a prospective validation of the prognostic impact of
CD49d is still warranted to definitively introduce this marker into the
routine clinical assessment of patients with CLL.
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Table 2. Multivariable Cox Regression Analysis of OS
Factor
Final Reduced Model Initial Full Model Univariate Model
HR 95% CI P HR 95% CI P HR 95% CI P
Age  65 years 3.25 2.18 to 4.84  .001 3.03 2.00 to 4.57  .001 2.75 1.87 to 4.02  .001
Unmutated IGHV 2.48 1.68 to 3.66  .001 1.99 1.29 to 3.07  .001 2.64 1.81 to 3.85  .001
CD49d  30% 2.26 1.57 to 3.25  .001 2.01 1.36 to 2.97  .001 2.31 1.62 to 3.29  .001
del17p 2.13 1.37 to 3.32  .001 2.22 1.41 to 3.50  .001 2.90 1.87 to 4.49  .001
Male sex 1.83 1.24 to 2.69 .0022 1.73 1.18 to 2.56 .0055 1.53 1.06 to 2.22 .0241
ALC  15  109/L 1.66 1.11 to 2.48 .0133 1.62 1.08 to 2.43 .0202 1.55 1.05 to 2.30 .0290
ZAP-70 — — — 1.45 0.95 to 2.21 .0864 2.27 1.57 to 3.27  .001
2M  ULN — — — 1.26 0.80 to 1.97 .3217 2.23 1.47 to 3.40  .001
CD38 — — — 1.21 0.82 to 1.78 .3447 1.98 1.38 to 2.82  .001
del11q — — — 1.19 0.70 to 2.04 .5244 1.35 0.82 to 2.23 .24
NOTE. Final model was multivariable analysis with backward stepwise elimination of nonsignificant predictors. All models were stratified by study site and clinical
stage. Total patient cases included, 1,117; events, 137.
Abbreviations: ALC, absolute lymphocyte count; 2M, 2-microglobulin; HR, hazard ratio; OS, overall survival; ULN, upper limit of normal.
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GLOSSARY TERMS
Concordance index (C-index): The concordance index is
the probability that given two randomly selected patients, the
patient with the worst outcome is, in fact, predicted to have the
worst outcome. The measure is similar to an area under the re-
ceiver operating characteristics curve and ranges from 0.5
(chance or coin flip) to 1.0 (perfect ability to rank patients).
Integrin: Integrins are cell-adhesion receptors that are in-
volved in two important pathways: cell-extracellular matrix and
cell-cell interactions, thus allowing for cell-cell and cell-
extracellular matrix communication. Functionally, integrins are
composed of two subunits (heterodimers), one belonging to the
 family and the other belonging to the  family.
Recursive partitioning: Multivariable analysis that generates a
clinically intuitive decision tree model in which the population is di-
vided into prognostic subgroups. This is achieved through multiple di-
chotomous divisions on the basis of a set of independent variables.
ZAP-70: Involved in T-cell activation and differentiation signals. Early
events in the activation of the T-cell receptor (CD3/TCR) include the
activation of non–receptor tyrosine kinases (eg, Src family) leading to
the phosphorylation of immunoreceptor, tyrosine-based activation mo-
tifs (ITAMs) in the cytoplasmic domains of the CD3/TCR  chains. The
phosphorylation of ITAMs is responsible for the recruitment and activa-
tion of -associated protein (ZAP)-70 via its SH2 domain, with subse-
quent recruitment and activation of other proteins.
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Fig A1. Decision tree resulting from recursive partitioning analysis of flow cytometry–measured prognostic variables applied to individual patient data for 2,972
patients. CD49d recoded at cutoff  30%; CD38 and ZAP-70 coded as originally performed in each center. CD49d was the most significant covariate for entire study
population and was selected by algorithm to split patient population into two terminal nodes. Horizontal line shows optimal split point and corresponding values (above
and below) of the complexity parameter (CP). Additional splits below generated daughter nodes without significantly different survival probability (shown for clarity and
iconographic purposes). Right branch of each split represents positivity of the variable; left branch, negativity. Kaplan-Meier curves at top left and top right estimate
overall survival (OS) of patients belonging to the CD49d and CD49d nodes, respectively. Kaplan-Meier curves at bottom estimate OS of patients belonging to
terminal nodes of the full-grown, unpruned tree. pos, positive.
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Fig A2. Bivariate analysis by Kaplan-Meier curves of CD49d expression in the context of chronic lymphocytic leukemia (CLL) subset expressing or not CD38
(left panels) or ZAP70 (right panels). (A) Overall survival. Blue lines indicate CD49d CLL; gold lines, CD49d CLL. P values determined using log-rank test. (Continued
on next page)
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Fig A2. (Continued). (B) Treatment-free survival. Blue lines indicate CD49d CLL; gold lines, CD49d CLL. P values determined using log-rank test.
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